Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis.

Proc Natl Acad Sci U S A · 2024 · PMC11317586 · PMID 39083422

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

At 30 mg/kg, a reduction was observed, however, this effect did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.